PDS Planning Inc Takes Position in Kenvue Inc. (NYSE:KVUE)

PDS Planning Inc acquired a new stake in shares of Kenvue Inc. (NYSE:KVUE) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 12,331 shares of the company’s stock, valued at approximately $265,000.

Other hedge funds have also made changes to their positions in the company. Clearstead Advisors LLC acquired a new stake in Kenvue in the 3rd quarter valued at approximately $25,000. Planned Solutions Inc. acquired a new stake in Kenvue in the 4th quarter valued at approximately $27,000. AdvisorNet Financial Inc acquired a new stake in Kenvue in the 3rd quarter valued at approximately $28,000. Global Retirement Partners LLC acquired a new stake in Kenvue in the 3rd quarter valued at approximately $28,000. Finally, Venturi Wealth Management LLC acquired a new stake in Kenvue in the 3rd quarter valued at approximately $28,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

Kenvue stock opened at $19.36 on Wednesday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.78 and a current ratio of 1.12. The business has a 50 day simple moving average of $19.84 and a 200 day simple moving average of $20.15. Kenvue Inc. has a one year low of $17.82 and a one year high of $27.80.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, February 8th. The company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.03. The company had revenue of $3.67 billion for the quarter, compared to analyst estimates of $3.78 billion. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The company’s quarterly revenue was down 2.7% on a year-over-year basis. Research analysts anticipate that Kenvue Inc. will post 1.15 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 28th. Shareholders of record on Wednesday, February 14th were paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 4.13%. The ex-dividend date was Tuesday, February 13th.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on KVUE shares. Royal Bank of Canada lowered their target price on Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a report on Friday, February 9th. JPMorgan Chase & Co. decreased their price objective on Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a report on Friday, February 9th. The Goldman Sachs Group started coverage on Kenvue in a report on Friday, March 1st. They set a “neutral” rating and a $20.00 price objective on the stock. Sanford C. Bernstein started coverage on Kenvue in a report on Thursday, April 11th. They set an “underperform” rating and a $18.00 price objective on the stock. Finally, William Blair started coverage on Kenvue in a report on Wednesday, April 3rd. They set a “market perform” rating on the stock. One research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $24.85.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.